 |
19 Diseases |  |
1 Trial |
|
1 Trial |  |
3388 News |  |
| «12...2627282930313233343536...4849» |
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] Occurrence of β-Lactamases among Enterobacterales Isolated from United States Hospitals: Results of the INFORM Surveillance Program for Ceftazidime-Avibactam () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_2179;
CAZ-AVI was very active against isolates tested, including isolates producing carbapenemases that displayed resistance to many comparator agents. Table
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] Testing the Synergistic Effect of Ceftazidime-Avibactam Plus Aztreonam on Metallobetalactamase-Producing Non-Fermenting Gram-negative Bacteria () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_2173;
Table The ability of ceftazidime-avibactam+aztreonam to reduce the MICs of Acinetobacter baumanii and MBL-producing Pseudomonas aeruginosa is a potentially promising therapeutic option when faced with growing antimicrobial resistance.
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] In Vitro Activity of Ceftazidime-avibactam and Comparators against KPC-producing Enterobacterales and Pseudomonas aeruginosa Collected in China as Part of the ATLAS Global Surveillance Program in 2019 () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_2163;
Among P. aeruginosa isolates, 89.8% were susceptible to CAZ-AVI, more than for any comparator except amikacin (AMK; 94.4% S). CAZ-AVI demonstrated very good in vitro activity against Enterobacterales and P. aeruginosa isolates from China, including those that harbor KPC.
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] In Vitro Activity of Ceftazidime-Avibactam and Comparator Agents Against Enterobacterales and Pseudomonas aeruginosa Collected < 48 Hours and ≥48 Hours Post-Admission from Pediatric Patients, ATLAS Surveillance Program 2016-2019 () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_2159;
Isolates with CAZ or aztreonam MICs ≥2 µg/mL ( Escherichia coli , Klebsiella spp., Proteus mirabilis ) or meropenem MICs ≥2 µg/mL (all Ent species) or ≥4 µg/mL ( Psa ) were screened for β-lactamase genes. CAZ-AVI could provide a valuable therapeutic option for treatment of CA and HA infections caused by Ent and Psa in pediatric patients.
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] In Vitro Activity of Ceftazidime-avibactam and Comparator Agents against Enterobacterales and Pseudomonas aeruginosa Collected from Patients with Bloodstream Infections as Part of the ATLAS Global Surveillance Program, 2017-2019 () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_2158;
Meropenem-nonsusceptible (MEM-NS) Eba and Pae isolates were screened for the presence of β-lactamase genes. CAZ-AVI provides a valuable therapeutic option for treating bloodstream infections caused by MBL-negative Eba and Pae isolates.
- [VIRTUAL] Antimicrobial susceptibilities of carbapenem-resistant Klebsiella pneumoniae (CRKP) isolates from a multi-state network of long-term acute care hospitals (LTACHs) () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_2156;
In contrast, there was a low prevalence of non-susceptibility to CZA, which received initial US Food and Drug Association approval in 2/2015, and PLZ, which was not commercially available during the study period. Cross-resistance between CZA and carbapenem/beta-lactamase combination antibiotics was uncommon.
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] In Vitro Activity of Ceftazidime-Avibactam and Comparator Agents Against MDR Enterobacterales and Pseudomonas aeruginosa Collected in Latin America During the ATLAS Global Surveillance Program 2018-2019 () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_2139;
MDR was defined as resistant (R) to ≥3 of 7 sentinel drugs: amikacin (AMK), aztreonam (ATM), cefepime (FEP), colistin (CST), levofloxacin (LVX), meropenem (MEM), and piperacillin-tazobactam (TZP)... These in vitro data suggest that CAZ-AVI can be an effective treatment option for infections caused by MDR Enterobacterales and P. aeruginosa collected in Latin America.
- Xerava (eravacycline) / SOM Biotech, Ewha Womans University, La Jolla Pharma, PAION
[VIRTUAL] Eravacycline in Bacteremia: A Case Series () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_2138;
ERV may be an option for bacteremia as demonstrated by clearance in four of five cases. More studies must be conducted as these reports show variable clinical outcomes.
- Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] Comparative Activity of Meropenem-Vaborbactam and Ceftazidime-Avibactam Against Multidrug-Resistant Enterobacter cloacae from Hospitals in Europe and United States () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_2133;
Meropenem-vaborbactam and ceftazidime-avibactam can be important options to treat infections caused by MDR ECL. Table.
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] Characterization and crystallization of OXA-935, a novel class D OXA-10-like beta-lactamase, found in Pseudomonas aeruginosa () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_2132;
Despite these differences, both enzymes confer high-level CTZ resistance. As we increasingly rely on β-lactam antimicrobial therapy (e.g.
- imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] In Vitro Activity of Cefiderocol and Comparator Agents against Molecularly characterized Carbapenem-resistant Enterobacterales Clinical Isolates Causing Infection in United States Hospitals (2020) () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_2127;
These data confirm C FDC as an important option for the treatment of infections caused by ENT and resistant subsets. Table
- Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] In Vitro Activity of Ceftazidime-Avibactam and Comparator Agents Against Enterobacterales from ICU and Non-ICU Wards Collected in Latin America and Globally as part of the ATLAS Surveillance Program 2017-2019 () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_2118;
and Proteus mirabilis with aztreonam or ceftazidime MIC >1 µg/ml... CAZ-AVI provides a valuable treatment option for infections caused by Enterobacterales that do not carry MBLs, including those from patients in ICU wards, where antimicrobial resistance is typically higher.
- Zerbaxa (ceftolozane /tazobactam) / Merck (MSD)
[VIRTUAL] Ceftolozane-Tazobactam Heteroresistance in Cystic Fibrosis Related Pseudomonas aeruginosa Infections () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_2117;
Comparatively, I-R retained better in vitro potency. C-T PHR exists among PSA isolates in the majority of our CF patients.
- cefepime/taniborbactam (cefepime/VNRX-5133) / VenatoRx
[VIRTUAL] ARGONAUT-V: Susceptibility of multidrug-resistant (MDR) Pseudomonas aeruginosa to Cefepime-Taniborbactam () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_1960;
Compared to MVB, CZA, and C/T, FTB demonstrated the greatest activity against the 197 P. aeruginosa strains tested, including many carbapenem-non-susceptible strains. Pending completion of clinical development, FTB may be a promising therapeutic option for MDR P. aeruginosa infections.
- Cedax (ceftibuten dihydrate) / Currax
[VIRTUAL] ARGONAUT-IV: Susceptibility of Carbapenem-resistant Klebsiellae to Ceftibuten/VNRX-5236 () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_1952;
The prodrug (VNRX-7145) allows for oral administration, making it a potential option for step-down therapy. Importantly, VNRX-5236 has a broader spectrum of activity than existing oral BLIs, opening new treatment options for resistant infections as a key addition to the existing antibiotic arsenal.
- rifampicin / Generic mfg.
[VIRTUAL] Hypermutability in Clinical Strains of Klebsiella pneumoniae: Role of the V76G Mutation in MutH () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_1904;
mutH V76 is crucial in MMR. Long-term colonization or recurrent infections in face of antibiotic exposure might predispose CRKP strains to HM.
- Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
[VIRTUAL] Susceptibility of Phenotypic Subsets of Pseudomonas aeruginosa Isolates to Cefiderocol and Comparator Agents from SIDERO-WT 2014-2019 () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_1681;
CFDC demonstrated potent in vitro activity against a variety of phenotypic subsets of MDR P. aeruginosa isolates as compared to agents that are commonly used to treat MDR PsA infections including strains NS to other agents. These data support the use of CFDC as an important treatment option for MDR PsA.
- cefepime hydrochloride / Generic mfg.
[VIRTUAL] Improved Susceptibility of Pseudomonas aeruginosa to Cefepime (CEF) at a Veterans Tertiary Care Hospital, over a 7-Year Period (2011-2017): The Impact of Antibiotic Rotation/Cycling and Reversal of Drug Resistance in P. aeruginosa () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_1049;
Despite the availability of ceftazidime-avibactam (CAZ-AVI) and ceftolozone-tazobactam (CFT-TAZO), CEF continues to be an empiric agent of choice in several institutions. Judicious antimicrobial use and antibiotic rotation play a significant role in reversing drug resistance in P. aeuruginosa.
- [VIRTUAL] Impact of an Antimicrobial Intake Process within a Post-acute Medical System () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_939;
An antibiotic intake form and process for review for five restricted antibiotics (ceftaroline, ceftazidime/avibactam, ceftolozane/tazobactam, fidaxomicin, meropenem/vaborbactam) was approved at the system ASP committee. Implementation of an antimicrobial intake process within a post-acute medical system resulted in a significant reduction in antibiotic consumption for five targeted antibiotics as well as overall antibiotic expenditure.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Performance Evaluation of the Gradient Diffusion Strip Method and Disk Diffusion Method for Ceftazidime-Avibactam Against Enterobacterales and Pseudomonas aeruginosa: A Dual-Center Study. (Pubmed Central) - Oct 5, 2021
However, the VME rate > 1.5% (5.45%) by the disk diffusion method. By comparison, the performance of the gradient diffusion strip method was better than that of the disk diffusion method.
- |||| aztreonam / Generic mfg., Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Very nice study evaluating synergy testing of Aztreonam and Ceftazidime/avibactam for Metallo-beta-lactamase producing gram negatives #IDWeek2021 @NM_IDSteward (Twitter) - Oct 3, 2021
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Retrospective data, Journal, Combination therapy: Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis. (Pubmed Central) - Oct 2, 2021
A trend of posttreatment resistance occurred more likely in ceftazidime-avibactam therapy than the combination therapy. Due to the limited number of studies that can be included, additional high-quality studies are needed to verify the above conclusions.
- |||| Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical: After failing ceftazidime-avibactam, audience (and @JGPharmD) favor using meropenem-vaborbactam as second line. #IDWeek2021 @ryankshields @ErinMcCreary https://t.co/h15ExQMHcg (Twitter) - Oct 1, 2021
- |||| Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical: @JGPharmD now discussing CRE epidemiology and management. >90% of audience picks ceftazidime-avibactam or meropenem-vaborbactam as first-line choice for CRE management😀 #IDWeek2021 (Twitter) - Oct 1, 2021
- || Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Review, Journal: Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa. (Pubmed Central) - Sep 29, 2021
Although real-world data are limited, favourable outcomes with ceftazidime-avibactam treatment have been reported in some patients with MDR and XDR P. aeruginosa infections. Thus, ceftazidime-avibactam may have a potentially important role in the management of serious and complicated P. aeruginosa infections, including those caused by MDR and XDR strains.
- ||| Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Enrollment open, Gram negative: Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults (clinicaltrials.gov) - Sep 27, 2021
P4, N=60, Recruiting, Sponsor: Pfizer
Thus, ceftazidime-avibactam may have a potentially important role in the management of serious and complicated P. aeruginosa infections, including those caused by MDR and XDR strains. Not yet recruiting --> Recruiting
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Variability of Beta-Lactam Broth Microdilution for Pseudomonas aeruginosa. (Pubmed Central) - Sep 24, 2021
Piperacillin-tazobactam exhibited the highest degree of variability with 74% AA and 94%% EA. The implications of MIC variability are extensive as the MIC is essential for multiple facets of microbiology, such as the development of new compounds and susceptibility tests, dose optimization and pharmacokinetic/pharmacodynamic (PK/PD) targets for individual patients.
- || Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical, Journal: Evolutionary Trajectories toward Ceftazidime-Avibactam Resistance in Klebsiella pneumoniae Clinical Isolates. (Pubmed Central) - Sep 24, 2021
When expressed in Escherichia coli recipient cells cloned in the high-copy number pTOPO vector, the Ω loop mutated variants showed CZA-resistant phenotype associated with susceptibility to carbapenems, while KPC variants with insertions in the 270-loop showed residual activity on carbapenems. The investigation of CZA-resistance mechanisms offered the unique opportunity to study vertical, horizontal, and oblique evolutionary trajectories of K. pneumoniae high-risk clones.
- | cefepime/zidebactam IV (WCK 5222) / Wockhardt
Preclinical, Journal: In vitro activity of cefepime/zidebactam (WCK 5222) against recent Gram-negative isolates collected from high resistance settings of Greek hospitals. (Pubmed Central) - Sep 22, 2021
Other antibiotics including colistin showed limited activity against A. baumannii. The activity of cefepime/zidebactam against multi-drug-resistant isolates is attributable to zidebactam mediated novel β-lactam-enhancer mechanism.
- || Xerava (eravacycline) / SOM Biotech, Ewha Womans University, La Jolla Pharma, PAION, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical, Journal: Activity of cefiderocol, ceftazidime-avibactam, and eravacycline against extended-spectrum cephalosporin-resistant Escherichia coli clinical isolates (2012-20017) in relation to phylogenetic background, sequence type 131 subclones, bla genotype, and coresistance. (Pubmed Central) - Sep 15, 2021
Cefiderocol, ceftazidime-avibactam, and eravacycline MICs tended to be higher among isolates resistant (vs. susceptible) to diverse comparators. Thus, cefiderocol, ceftazidime-avibactam, and eravacycline are promising carbapenem-sparing alternatives for treating ESCREC infections, and their strength of activity varies in relation to diverse bacterial characteristics.
- || Clinical, Observational data, Journal: Cost of off-label antibiotic therapy for bone and joint infections: a 6-year prospective monocentric observational cohort study in a referral centre for management of complex osteo-articular infections. (Pubmed Central) - Sep 14, 2021
On the one hand, the introduction of the generic drugs of daptomycin and linezolid has significantly decreased the share of old ETs, but, on the other hand, the need for new ETs to treat infections associated with more resistant pathogens has not led to decrease in the overall costs. A drastic price reduction of generic drugs is essential to limit the costs associated with more complex BJIs.
- || Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical, Journal: Antimicrobial activity of ceftazidime/avibactam, ceftolozane/tazobactam and comparator agents against Pseudomonas aeruginosa from cystic fibrosis patients. (Pubmed Central) - Sep 14, 2021
Ceftazidime/avibactam and ceftolozane/tazobactam exhibited potent and broad-spectrum activity against P. aeruginosa isolated from CF patients worldwide, but higher susceptibility rates for ceftazidime/avibactam compared with ceftolozane/tazobactam were observed among the resistant subsets. Ceftazidime/avibactam and ceftolozane/tazobactam represent valuable options to treat CF pulmonary exacerbations caused by P. aeruginosa.
- ||| Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical: Neat! @ryankshields has some data on mutant AmpC that have ceftaz-avi and cefiderocol cross-resistance https://t.co/aTKKa4cRYb so will be interesting to see if there are mutations in both AmpC and KPC. What was the patient previously treated with? Was it CZA-S before? (Twitter) - Sep 14, 2021
- || aztreonam / Generic mfg., Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Ceftazidime-avibactam combination with aztreonam may work for Steno based on limited in vitro data and case reports. https://t.co/4KTmg2P4l7 (Twitter) - Sep 10, 2021
- || aztreonam / Generic mfg., Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
My understanding is that the carbepenemase steno produces is always an MBL, @OncIDPharmd @JosephSassineMD and yes that’s why Ceftaz-Avi plus Aztreonam makes sense. (Twitter) - Sep 10, 2021
- || Vabomere (meropenem/vaborbactam) / Melinta Therap, meropenem / Generic mfg., Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Meropenem? I would test vabomere and zavicefta (Twitter) - Sep 10, 2021
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD)
Journal: Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa. (Pubmed Central) - Sep 10, 2021
This study adds on to the growing knowledge of C/T resistance, particularly mutational resistance, and will aid in the design of future β-lactams and β-lactamase inhibitors. WGS proved to be a useful tool to understand the P. aeruginosa resistome and its contribution to emerging resistance in novel antimicrobial agents.
- ||| aztreonam / Generic mfg., Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Consider Ceftaz-Avi with aztreonam. Carbapenem resistant in Steno is mediated by metallo-beta-lactamase. Learned this pearl while rounding with @SuperBugDoc. (Twitter) - Sep 9, 2021
- ||| Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal, Adverse events, Serious adverse event: Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis. (Pubmed Central) - Sep 9, 2021
Among neurological AEs exhibiting significant disproportionality, encephalopathy with both antibiotics and mental status changes with ceftazidime-avibactam were retained in at least three cases after deduplication. Although rare, clinicians should monitor high-risk patients (i.e. individuals affected by haematological malignances, HIV infection, or treated with concomitant myelotoxic agents) for early unexpected occurrence of agranulocytosis with ceftolozane-tazobactam.
- || Teflaro (ceftaroline fosamil) / Sumitomo Dainippon, AstraZeneca, AbbVie, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical, Journal: Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime-avibactam: a surveillance study from the ATLAS program (2012-2016). (Pubmed Central) - Sep 8, 2021
The global antimicrobial susceptibilities to ceftaroline and ceftazidime-avibactam were, in general, stable from 2012 to 2016, but a marked reduction in the susceptibilities of specific species and CR-P. aeruginosa to ceftazidime-avibactam was observed.
- | Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: β-lactamase-mediated resistance in MDR-Pseudomonas aeruginosa from Qatar. (Pubmed Central) - Sep 8, 2021
aeruginosa isolates from Qatar are highly resistant to antipseudomonal β-lactams. High-risk STs are predominant in Qatar and their associated MDR phenotypes are a cause for considerable concern.
- | Journal: A Critical Evaluation of Newer β-Lactam Antibiotics for Treatment of Pseudomonas aeruginosa Infections. (Pubmed Central) - Sep 8, 2021
Selection of one agent over another should consider availability, turnaround of susceptibility testing, and product cost. Efficacy data specific for pseudomonal infections are limited, and there are no direct comparisons between the newer agents.
- || Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical, Journal: First detection of a plasmid-encoded New-Delhi metallo-beta-lactamase-1 (NDM-1) producing Acinetobacter baumannii using whole genome sequencing, isolated in a clinical setting in Benin. (Pubmed Central) - Sep 8, 2021
Strict control and prevention measures should be taken, once NDM-1 positive A. baumannii has been identified to prevent transfer of this resistance gene to other Enterobacterales. Capacity building is required by governmental agencies to provide suitable antibiotic treatment options and strategies, in combination with strengthening laboratory services for detection and surveillance of this pathogen.
- || Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical, Journal: Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against Pseudomonas aeruginosa from patients with cystic fibrosis. (Pubmed Central) - Sep 8, 2021
Capacity building is required by governmental agencies to provide suitable antibiotic treatment options and strategies, in combination with strengthening laboratory services for detection and surveillance of this pathogen. ETEST methods performed conservatively for most antibiotics against this challenging collection of P. aeruginosa from patients with CF.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Emergence of a KPC Variant Conferring Resistance to Ceftazidime-Avibactam in a Widespread ST11 Carbapenem-Resistant Klebsiella pneumoniae Clone in China. (Pubmed Central) - Sep 7, 2021
This CZA resistance mediated by KPC-74 could be selected after CZA therapy and evolved to be more diverse and heterogeneous. Surveillance of CZA resistance is urgently needed in clinical settings.
- || Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
I wonder, what would a situation in which only a carbapenem is left to be used for treatment? PsA R to ceftazidime-avibactam? I miss ceftolozane-tazobactam so much. @a_hamprecht @wfwrighID @DrToddLee @SuperBugDoc (Twitter) - Sep 7, 2021
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Experience of Ceftazidime/avibactam in a UK tertiary cardiopulmonary specialist center. (Pubmed Central) - Sep 4, 2021
Surveillance of CZA resistance is urgently needed in clinical settings. Our study showed that Antimicrobial stewardship interventions led to a more appropriate use of Ceftazidime/avibactam (as measured by duration of therapy), preserving it as a treatment option for MDR infections.
- || ceftriaxone / Generic mfg.
Clinical, Journal: Clinical syndromes and treatment location predict utility of carbapenem sparing therapies in ceftriaxone-non-susceptible Escherichia coli bloodstream infection. (Pubmed Central) - Sep 4, 2021
All tested agents could be used to replace a significant volume of carbapenem therapy. Establishing stability of these agents for use in OPAT is required for maximizing their use as carbapenem sparing agents while randomized clinical data is awaited for some of these agents in resistant E. coli bacteremia.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Preclinical, Journal: Contribution of Drugs Interfering with Protein and Cell Wall Synthesis to the Persistence of Pseudomonas aeruginosa Biofilms: An In Vitro Model. (Pubmed Central) - Sep 4, 2021
Moreover, a positive correlation between tobramycin exposure, biofilm production and c-di-GMP levels was observed. The presented data could allow a deeper understanding of bacterial population dynamics during the treatment of recurrent PA infections and provide a reliable evaluation of the real efficacy of the antibiotic treatments against the bacterial population within the CF lung.
- | Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Retrospective data, Journal: Effectiveness of Ceftazidime-Avibactam versus Colistin in Treating Carbapenem-Resistant Enterobacteriaceae Bacteremia. (Pubmed Central) - Sep 2, 2021
The presented data could allow a deeper understanding of bacterial population dynamics during the treatment of recurrent PA infections and provide a reliable evaluation of the real efficacy of the antibiotic treatments against the bacterial population within the CF lung. Ceftazidime-avibactam was associated with a lower risk of 14-day mortality than colistin in patients with CRE bacteremia.